Prosecution Insights
Last updated: October 02, 2026
Application No. 18/668,446

HUMANIZED ANTI-IL-1R3 ANTIBODIES

Non-Final OA §112
Filed
May 20, 2024
Priority
May 06, 2016 — EU 16168617.5 +3 more
Examiner
LI, RUIXIANG
Art Unit
Tech Center
Assignee
Sanofi S.A.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
5m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
612 granted / 1029 resolved
-0.5% vs TC avg
Strong +19% interview lift
Without
With
+18.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
48 currently pending
Career history
1057
Total Applications
across all art units

Statute-Specific Performance

§101
6.4%
-33.6% vs TC avg
§103
19.4%
-20.6% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
46.1%
+6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1029 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Application, Amendments, and/or Claims 1. Claims 20-37 are pending and currently under consideration. Information Disclosure Statement 2. The information disclosure statement filed on 04/22/2025 has been considered in part by the Examiner and an initialed copy of the form PTO-1449 is attached to the office action. Drawings 3. The drawings filed on 05/20/2024 are accepted by the Examiner. Claim Rejections[Symbol font/0xBE]35 USC § 112 (b) 4. The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. Claims 20-37 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claims 20-23, 28, and 33 recite in preamble “an IL1R3-mediated disease”. The specification only provides some examples of the IL1R3-mediated diseases (see, e.g., page 24, line 1). Neither the art nor the specification provides an unambiguous definition for the term. It is unclear what the IL1R3-mediated disease is, rendering the claims indefinite. Claims 24-27, 29-32, and 34-37 are rejected as dependent claims. Conclusions 6. No claims are allowed. Advisory Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vanessa Ford, can be reached on (571) 272-0857. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197. /RUIXIANG LI/Primary Examiner, Art Unit 1674 September 23, 2026
Read full office action

Prosecution Timeline

May 20, 2024
Application Filed
Sep 25, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12729238
NANODISC-SPECIFIC ANTIGEN-BINDING CHIMERIC PROTEINS
4y 4m to grant Granted Sep 08, 2026
Patent 12723068
STABILIZED MHC I
4y 11m to grant Granted Sep 01, 2026
Patent 12698334
ANTI-IL-1R3 ANTIBODIES FOR USE IN INFLAMMATORY CONDITIONS
3y 4m to grant Granted Aug 04, 2026
Patent 12692478
POPULATIONS OF ENRICHED REGULATORY T CELLS AND METHODS FOR PRODUCING SAME
4y 4m to grant Granted Jul 28, 2026
Patent 12679890
ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOF
4y 0m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
78%
With Interview (+18.6%)
2y 9m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1029 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month